PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Phase 2

Terminated

Conditions: Genes, BRCA 1
Locally Advanced or Metastatic Solid Tumors

Interventions: Drug: Avelumab
Drug: Talazoparib

First Posted Date: 2018-06-21

Last Posted Date: 2023-09-25

Lead Sponsor: Pfizer

Target Recruit Count: 202

Registration Number: NCT03565991

Locations: 🇺🇸
Northside Hospital, Inc. - GCS/Annex, Atlanta, Georgia, United States
🇺🇸
Northside Hospital, Inc. - GCS/Northside, Atlanta, Georgia, United States
🇺🇸
Atlanta Cancer Care - Atlanta, Atlanta, Georgia, United States

and more 83 locations

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

Phase 2

Terminated

Conditions: Pneumococcal Infections

Interventions: Biological: Multivalent
Biological: Prevnar 13

First Posted Date: 2018-06-08

Last Posted Date: 2021-11-30

Lead Sponsor: Pfizer

Target Recruit Count: 565

Registration Number: NCT03550313

Locations: 🇺🇸
Emmaus Research Center, Inc., Anaheim, California, United States
🇺🇸
Madera Family Medical Group, Madera, California, United States
🇺🇸
Mobile Pediatric Clinic, Mobile, Alabama, United States

and more 44 locations

Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India

Phase 4

Completed

Conditions: Vaccines

Interventions: Biological: 13vPnC

First Posted Date: 2018-06-07

Last Posted Date: 2020-09-30

Lead Sponsor: Pfizer

Target Recruit Count: 301

Registration Number: NCT03548337

Locations: 🇮🇳
Kanchi Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu, India
🇮🇳
KEM Hospital Research Centre, Pune, Maharashtra, India
🇮🇳
Bharati Vidyapeeth University Medical College, Pune, Maharashtra, India

and more 4 locations

Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.

Phase 4

Withdrawn

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)

Interventions: Drug: methylphenidate HCl ERCT

First Posted Date: 2018-06-06

Last Posted Date: 2018-11-01

Lead Sponsor: Pfizer

Registration Number: NCT03546400

Lorlatinib Renal Impairment Study

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Lorlatinib

First Posted Date: 2018-05-31

Last Posted Date: 2021-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT03542305

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Prism Clinical Research, LLC, Saint Paul, Minnesota, United States

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

Phase 4

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: Pimecrolimus cream, 1%
Drug: Crisaborole ointment, 2%
Drug: Hydrocortisone butyrate cream, 0.1%
Drug: Crisaborole Vehicle

First Posted Date: 2018-05-29

Last Posted Date: 2022-01-10

Lead Sponsor: Pfizer

Target Recruit Count: 237

Registration Number: NCT03539601

Locations: 🇺🇸
Arlington Research Center, Inc., Arlington, Texas, United States
🇩🇪
Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lubeck, Schleswig-holstein, Germany
🇵🇱
Barbara Rewerska Diamond Clinic, Krakow, Malopolska, Poland

and more 29 locations

4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: PF-06882961
Drug: Placebo

First Posted Date: 2018-05-29

Last Posted Date: 2020-07-01

Lead Sponsor: Pfizer

Target Recruit Count: 98

Registration Number: NCT03538743

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
Qps-Mra,Llc, South Miami, Florida, United States

and more 1 locations

"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"

Completed

Conditions: Carcinoma, Renal Cell

First Posted Date: 2018-05-29

Last Posted Date: 2022-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 157

Registration Number: NCT03538717

Locations: 🇪🇸
Complejo Hospitalario la Mancha Centro, Alcazar de San Juan, Ciudad REAL, Spain
🇪🇸
Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
Hospital Universitario Mutua Terrassa, Terrassa, Barcelona, Spain

and more 37 locations

A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD

Phase 4

Withdrawn

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
Drug: Placebo

First Posted Date: 2018-05-24

Last Posted Date: 2018-11-01

Lead Sponsor: Pfizer

Registration Number: NCT03536390

Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06865571 administered Day 7-14
Drug: PF-06865571 administered Day 1-14
Drug: PF-05221304 administered Day 1-14
Drug: PF-05221304 administered Day 7-14

First Posted Date: 2018-05-23

Last Posted Date: 2018-09-18

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT03534648

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy